The Epithelial-to-Mesenchymal Transition (EMT) in the Development and Metastasis of Malignant Pleural Mesothelioma
Open accessThe DOI matches its Crossref record; 91 of the 93 references it cites were found in a registry or an index.
Abstract
Malignant pleural mesothelioma (MPM) is an aggressive tumor mainly associated with asbestos exposure and is characterized by a very difficult pharmacological approach. One of the molecular mechanisms associated with cancer onset and invasiveness is the epithelial-to-mesenchymal transition (EMT), an event induced by different types of inducers, such as transforming growth factor β (TGFβ), the main inducer of EMT, and oxidative stress. MPM development and metastasis have been correlated to EMT; On one hand, EMT mediates the effects exerted by asbestos fibers in the mesothelium, particularly via increased oxidative stress and TGFβ levels evoked by asbestos exposure, thus promoting a malignant phenotype, and on the other hand, MPM acquires invasiveness via the EMT event, as shown by an upregulation of mesenchymal markers or, although indirectly, some miRNAs or non-coding RNAs, all demonstrated to be involved in cancer onset and metastasis. This review aims to better describe how EMT is involved in driving the development and invasiveness of MPM, in an attempt to open new scenarios that are useful in the identification of predictive markers and to improve the pharmacological approach against this aggressive cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ROS can sustain EMT via TGF-β1 [89].”
From Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma (2023) · cites this paper as [89]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Adhikary, G., Grun, D., Alexander, H. R., Friedberg, J. S., Xu, W., Keillor, J. W., Kandasamy, S., & Eckert, R. L. (2018) · Oncotarget · doi:10.18632/oncotarget.26130 · Cited by 40
RetractedNew insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer
Dongre, A., & Weinberg, R. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0080-4 · Cited by 3,876
Snail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype?
Peinado, H., Olmeda, D., & Cano, A. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2131 · Cited by 3,121
TGF-β-induced epithelial to mesenchymal transition
Xu, J., Lamouille, S., & Derynck, R. (2009) · Cell Research · doi:10.1038/cr.2009.5 · Cited by 2,804 · cited 1×
“In a non-SMAD-dependent way, TGFβ-induced EMT involves some signaling pathways, such as mitogen-activated protein kinase (MAPK), PI3K, NF-κB and small GTPases of the Rho family [4,48,49]; among these non-SMAD signaling pathways, PI3K actives Akt, which inhibits GSK-3β in turn, a regulator of SNAI1, SNAI2, Twist and ZE…”
BackgroundGuidelines and definitions for research on epithelial-mesenchymal transition
Yang, J., Antin, P., Berx, G., Blanpain, C., Brabletz, T., Bronner, M., Campbell, K., Cano, A., Casanova, J., Christofori, G., et al. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0237-9 · Cited by 2,226
Burk, U., Schubert, J., Wellner, U., Schmalhofer, O., Vincan, E., Spaderna, S., & Brabletz, T. (2008) · EMBO reports · doi:10.1038/embor.2008.74 · Cited by 1,722
Baas, P., Scherpereel, A., Nowak, A. K., Fujimoto, N., Peters, S., Tsao, A. S., Mansfield, A. S., Popat, S., Jahan, T., Antonia, S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32714-8 · Cited by 1,215 · cited 2×
“Currently, a combination of immune checkpoint inhibitors (ICIs), monoclonal antibodies (mAbs), anti-programmed cell death 1 (PD-1), nivolumab and anti-CTL antigen 4 (CTLA-4) ipilimumab [10] was approved by the Food and Drug Administration (FDA) for first-line treatment of unresectable MPM based on CheckMate 743, which…”
BackgroundMethodTGF-β-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis
Hao, Y., Baker, D., & ten Dijke, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112767 · Cited by 1,142
Woo, E. Y., Chu, C., Goletz, T. J., Schlienger, K., Yeh, H., Coukos, G., Rubin, S. C., Kaiser, L. R., & June, C. H. (2001) · PubMed · Cited by 1,108
Malignant cells facilitate lung metastasis by bringing their own soil
Duda, D. G., Duyverman, A. M. M. J., Kohno, M., Snuderl, M., Steller, E. J. A., Fukumura, D., & Jain, R. K. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016234107 · Cited by 594
Cited by
Fiorilla, I., Martinotti, S., Todesco, A. M., Bonsignore, G., Cavaletto, M., Patrone, M., Ranzato, E., & Audrito, V. (2023) · Cells · doi:10.3390/cells12162048 · Cited by 39
Fennell, D. A., Sekido, Y., Baas, P., Husain, A. N., Fontecedro, A. C., Lim, E. K. S., Opitz, I., Simone, C. B., Brims, F., & Wong, M. C. S. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00640-3 · Cited by 47
“The exact cause of EMT in mesothelioma remains unclear, but it likely involves the acquisition of genomic abnormalities, positive selection of tumour cells and the tumour microenvironment (TME), which includes stimulation by TGFβ 66 .”
InfluentialFakhri, S., Moradi, S. Z., Faraji, F., Kooshki, L., Webber, K. J., & Bishayee, A. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10136-9 · Cited by 34
TGF-β as Predictive Marker and Pharmacological Target in Lung Cancer Approach
Ramundo, V., Palazzo, M. L., & Aldieri, E. (2023) · Cancers · doi:10.3390/cancers15082295 · Cited by 35
“In particular, this cytokine is the major driver of the epithelial to mesenchymal transition (EMT), a reversible physiological process involved in tumor onset, progression, and metastasis [8].”
BackgroundSelf-citationAbd‐Elmawla, M. A., Mageed, S. S. A., AL‐Noshokaty, T. M., Elballal, M. S., Abulsoud, A. I., Elshaer, S. S., El-Husseiny, A. A., Fathi, D., Midan, H. M., Rizk, N. I., et al. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154817 · Cited by 26
Hu, X., Jiang, C., Hu, N., & Hong, S. (2023) · Aging · doi:10.18632/aging.204594 · Cited by 20
Kuang, Y., Cheng, Y., Wang, J., Li, H., Cao, X., & Wang, Y. (2022) · Cancer Medicine · doi:10.1002/cam4.5432 · Cited by 22
Pouliquen, D., Boissard, A., Henry, C., Coqueret, O., & Guette, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.934534 · Cited by 18
Dai, Z., Huang, Q., Huang, X., Zhu, C., Zahid, K. R., Liu, T., Li, Q., Wu, C., Peng, M., Xiao, X., et al. (2022) · Molecular Carcinogenesis · doi:10.1002/mc.23492 · Cited by 14
“Among these, the TGF‐β pathway has been confirmed that it involved in a series of biological processes, including tumor development and metastasis, ECM remodeling, and immune‐suppression, which was found to play a key role in multiple tumors' EMT phenotype.(29) The TGF‐β family ligand dimer forms a complex with the co…”
BackgroundCioce, M., Rutigliano, D., Puglielli, A., & Fazio, V. M. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2022.56 · Cited by 13
Omics Overview of the SPARC Gene in Mesothelioma
Wu, L., & de Perrot, M. E. (2023) · Biomolecules · doi:10.3390/biom13071103 · Cited by 12
“The increased expression of the SPARC gene in MESO is associated with increased epithelial-to-mesenchymal transition (EMT), which is a process by which epithelial cells undergo a transformation to become more motile and invasive [56].”
BackgroundÇakıroğlu, E., Eris, S., Öz, Ö., Karakülah, G., & Şentürk, Ş. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07587-z · Cited by 15
“The cumulative evidence from these studies accentuates BUB1 ’ s capacity to fuel malignant phenotypes in MPM cells, strengthening its value as a therapeutic target.”
Gu, F., Zhou, Y., Tian, L., Chen, J., Zhang, C., Huang, Z., Yu, W., & Xie, K. (2024) · Scientific Reports · doi:10.1038/s41598-024-72198-1 · Cited by 10
Feng, G., Chen, C., & Luo, Y. (2023) · Oncology Reports · doi:10.3892/or.2023.8647 · Cited by 11
Masciale, V., Banchelli, F., Grisendi, G., Samarelli, A. V., Raineri, G., Rossi, T., Zanoni, M., Cortesi, M., Bandini, S., Ulivi, P., et al. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107994 · Cited by 12
“In particular, this cytokine is the main inducer of the reversible physiological process known as EMT, which is implicated in the growth, dissemination, and metastasis of tumors (511).”
Park, M. N., Kim, H. S., Park, S., Syahputra, R. A., Delfino, D. V., Ko, S., & Kim, B. (2026) · Redox Biology · doi:10.1016/j.redox.2026.104111 · Cited by 9
“Dynamic EMT/MET switching has been visualized in live tumor cells using dual fluorescent sensor systems, demonstrating that therapeutic stress actively selects for EMT-plastic subpopulations capable of oscillating between epithelial and mesenchymal states [54,55].”
Characterization of KLHL14 anti-oncogenic action in malignant mesothelioma
Canciello, A., Dominguez-Benot, R., Barboni, B., Giordano, A., & Morrione, A. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e27731 · Cited by 7
“Indeed, it has been demonstrated how asbestos exposure increases TGF-β levels, which in turn promote a malignant phenotype and invasiveness via EMT events [17].”
You, Y., Gao, C., Wu, J., Qu, H., Xiao, Y., Kang, Z., Li, J., & Hong, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113084 · Cited by 6
“The EMT is a morphogenetic altered and reversible process, during which an epithelial cell loses its own features by reducing some epithelial proteins expression (E-cadherin, β-catenin, and ZO-1) and by acquiring a mesenchymal phenotype, thereby increasing mesenchymal proteins expression (N-cadherin, Fibronectin, Vime…”
BackgroundFeng, L., Li, T., Xu, B., Huang, J., Xia, H., Jiang, Z., Chen, J., Pan, S., Zhang, X., Jiang, H., et al. (2024) · Environmental Pollution · doi:10.1016/j.envpol.2024.124928 · Cited by 5
Sun, Z., Ding, C., Wang, Y., Zhou, H., & Song, W. (2024) · Journal of Bioscience and Bioengineering · doi:10.1016/j.jbiosc.2024.10.002 · Cited by 5
LncRNAs and related molecular basis in malignant pleural mesothelioma: Challenges and potential
Xu, X., Li, H., Xie, M., Zhou, Z., Wang, D., & Mao, W. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104012 · Cited by 5
Ramundo, V., Zanirato, G., Palazzo, M. L., Riganti, C., & Aldieri, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612570 · Cited by 7
“The main etiological factor of MPM is the exposure to asbestos: even if the pathogenetic mechanisms involved are not yet fully understood, it has been widely reported that asbestos fibers in mesothelial cells evoke some events that have been associated with MPM development, such as chronic inflammation, accentuated ox…”
BackgroundSelf-citationRetractedBruno, R., Poma, A. M., Alì, G., Distefano, C., Proietti, A., Chella, A., Lucchi, M., Melfi, F. M. A., Franco, R., & Fontanini, G. (2022) · Diagnostics · doi:10.3390/diagnostics12030674 · Cited by 5
“These deregulated genes impact on EMT process, leading from epithelial to mesenchymal phenotype [19].”
BackgroundERS Congress 2024: highlights from the Thoracic Oncology Assembly
Catarata, M. J., Chaurasia, S., Magouliotis, D. E., Neilly, M. D. J., Pedroso, A. R., Tomos, I. P., Xhemalaj, D., Charpidou, A. G., Rahman, N. M., Hardavella, G. F., et al. (2025) · ERJ Open Research · doi:10.1183/23120541.01171-2024 · Cited by 3
“Accordingly, mesothelial – mesenchymal transition is now considered a core mediator of progression, driving the disease becoming sarcomatoid [29].”
Integrative eQTL and Mendelian randomization analysis reveals key genetic markers in mesothelioma
Li, J., Wang, X., Lin, Y., Li, Z., & Xiong, W. (2025) · Respiratory Research · doi:10.1186/s12931-025-03219-4 · Cited by 5
“Additionally, TACC3 can promote the EMT of gastric cancer cells through the ERK/Akt/cyclin D1 signaling pathway, which is a critical process in the metastasis of mesothelioma [42, 43].”
Stella, G. M., Marchiò, C., Bari, E., Ferrarotti, I., Bertuccio, F. R., Gennaro, A. D., Abbott, D. M., Putignano, P., Campo, I., Torre, M. L., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043496 · Cited by 4
“mesothelial cells and, once activated, promotes the acquisition by a transformed cell of more aggressive phenotypes and invasive capacity markers [42].”
BackgroundMesothelial Cells in Fibrosis: Focus on Intercellular Crosstalk
Бакаленко, Н. И., Kuznetsova, E., Дергилев, К. В., Beloglazova, I. B., & Malashicheva, A. (2026) · Biomolecules · doi:10.3390/biom16010085 · Cited by 4
Why the MARS2 Trial Does Not Mean the End of All Mesothelioma Surgery
Waller, D. A., Bilancia, R., Ventura, L., Tenconi, S., Socci, L., & Billè, A. (2025) · Cancers · doi:10.3390/cancers17050724 · Cited by 7
“We have reported an association with the epithelial-to-mesenchymal transition (EMT) [17] between pre-and postoperative histology and neoadjuvant chemotherapy [18].”
Tong, X., Zhu, T., Ma, L., Yang, X., Li, C., Liu, Y., Qin, X., Ding, Y., Xia, H., & Liu, Y. (2025) · BMC Cancer · doi:10.1186/s12885-025-14341-3 · Cited by 5
“The epithelial-mesenchymal transition (EMT) is a reversible biological process characterized by the conversion of stationary epithelial cells into motile mesenchymal cells [15].”
Damane, B. P., Mkhize‐Kwitshana, Z. L., Mehrotra, R., Mulaudzi, T. V., & Dlamini, Z. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23168991 · Cited by 4
Alay, A., Marín, R., Aliagas, E., Gausachs, M., Ruiz-Gil, M., Macía, I., Ojanguren, A., Padrones, S., Dorca, E., Brenes, J., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108679 · Cited by 2
Wu, M.-Y., Shi, X., Shan, J., Wang, R., Wang, Y., Li, J., Tian, D., & Xu, H. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e11751 · Cited by 3
“TNF-α is secreted by Th1 cells, which can directly or indirectly promote the development of EMT (Ramundo et al., 2021).”
BackgroundMagouliotis, D. E., Minervini, F., Cioffi, U., Simone, M. D., Patrini, D., & Scarci, M. (2025) · Cells · doi:10.3390/cells14080585 · Cited by 3
“The enhanced enhanced invasive properties of mesenchymal-like tumor cells contribute to the aggressive nature of MPM and its poor prognosis [1]. invasive of mesenchymal-like tumor cells contribute to the aggressive nature of poor prognosis [1]. spread and distant metastasis.”
InfluentialJiang, S., Berkcan, S., Perriraz, N., Triponez, F., & Serre‐Beinier, V. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262010127 · Cited by 1
“MM is classified into three main subtypes: epithelioid (75% of all cases), biphasic (15%), and sarcomatoid (10%), each exhibiting distinct epithelial–mesenchymal transition (EMT) phenotypes and varying resistance to treatment [8,9].”
Laure, A., Rigutto, A., Kirschner, M. B., Opitz, L., Grob, L., Opitz, I., Felley‐Bosco, E., Hiltbrunner, S., & Fontecedro, A. C. (2023) · Cancers · doi:10.3390/cancers15102813 · Cited by 2
“Previous studies revealed an association of EMT with cancer onset and invasiveness in MPM [70] leading to in vitro experiments and preclinical trials using EMT-targeting drugs and TGFβ inhibitors showed promising results in these studies [71].”
ResultExpression of stathmin in asbestos-like fibers-induced mesothelioma: A preliminary report.
Lombardo, C., Broggi, G., Vitale, E., Ledda, C., Loreto, C., Matera, S., Hagnäs, M. P., Caltabiano, R., & Filetti, V. (2023) · PubMed · doi:10.14670/hh-18-649 · Cited by 2
Ventura, L., Lee, M., Baranowski, R., Hargrave, J., Sheaff, M. T., & Waller, D. A. (2023) · Interdisciplinary CardioVascular and Thoracic Surgery · doi:10.1093/icvts/ivad145 · Cited by 1
“Epithelial-to-mesenchymal transition is characterized by an upregulation of mesenchymal markers or some miRNAs or non-coding RNAs and results in increased tumour cell mobility, invasiveness, apoptosis resistance and even resistance to chemotherapy [9].”
BackgroundXiao, J. F., Zhang, F., Liu, W., & Zang, W.-D. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.02.506322 · Cited by 1
Voloaca, O. M. (2022) · Sheffield Hallam University · doi:10.7190/shu-thesis-00479
Effect of dihydromyricetin combined with cisplatin on treatment of lung cancer cell A549Preprint
Hao, M., Pang, C., Zhu, W., Zhao, H., Zhang, W., Yang, F., Song, Z., Sun, D., & Zuo, Y. (2023) · Research Square · doi:10.21203/rs.3.rs-2880334/v1
Асбест әсерінен туындаған өкпе аурулары жасушалық механизмдеріндегі митохондрияның рөлі
Bersimbaev, R. I., & Ainagulova, G. S. (2024) · BULLETIN of the L N Gumilyov Eurasian National University BIOSCIENCE Series · doi:10.32523/2616-7034-2024-146-1-160-187 · Cited by 1
Unveiling cancer stem cell marker networks: A hypergraph approach
Margarit, D. H., Paccosi, G., Reale, M. V., & Romanelli, L. (2025) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2025.108684 · Cited by 1
Lu, Q., Liu, C., Xu, M., Hu, Z., Yin, H. Y., & Yang, J. (2025) · Journal of International Medical Research · doi:10.1177/03000605251389356
“22 Mir-137 was closely associated with the invasion and migration of MPM by targeting YBX1 23 as well as CD70, 24 ADAM10, 25 and BNDF. 26 However, these parameters and methods were invasive and impractical for clinicians to apply due to lack of efficacy or convenience.”
Luan, J., Zong, X., Zhou, Q., Liu, Q., Zhang, J., Hu, J., & Liu, W. (2026) · Journal of the Indian Chemical Society · doi:10.1016/j.jics.2026.102717
Almonti, V., Mirata, S., Passalacqua, M., Vernazza, S., Tirendi, S., Ferrando, S., Risso, B., Grasselli, E., Atanasio, G. D. N., Bassi, A. M., et al. (2026) · Archives of Toxicology · doi:10.1007/s00204-026-04471-3
“If maintained over time, early molecular alterations could evolve into transformation-associated pathways, including EMT activation, a crucial step for the onset of chronic lung diseases and cancer development like MPM and lung carcinoma (Ramundo et al. 2021 ).”
Aktar, T., Modak, S., Majumder, D., Samanta, S., & Maiti, D. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110325
Metadata
- Authors
- Ramundo, V., Zanirato, G., & Aldieri, E.
- Affiliations
- University of Turin (IT)
- Corresponding author
- Aldieri, Elisabetta
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-11-11
- Volume
- 22
- Issue
- 22
- Pages
- 12216
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8621591
- OpenAlex
- W3214151214
- Cited by
- 46
- References
- 93
- Citations by year
- 2026: 5 · 2025: 11 · 2024: 6 · 2023: 14 · 2022: 10
- FWCI
- 1.21
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- epithelial-mesenchymal transition, malignant pleural mesothelioma, asbestos exposure, TGF-beta, oxidative stress, tumor invasion, metastasis, mesenchymal markers, microRNA, non-coding RNA, predictive biomarkers, mesothelium
- MeSH terms
- Mesothelioma, Malignant, Humans, Neoplasm Metastasis, Neoplasm Proteins, Pleural Neoplasms, RNA, Neoplasm, Biomarkers, Tumor, Transforming Growth Factor beta, MicroRNAs, Epithelial-Mesenchymal Transition
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.